Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Oncology, and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Galectin-3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Galectin-3 Full-Length, CRD & Mutant Protein High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 Expressed. Theoretical MW confirmed. |
View LGALS3 Products |
| Gene Delivery | Galectin-3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View LGALS3 Products |
| Benchmark Ab | Anti-Galectin-3 (Recombinant Benchmark) Sequence-verified positive control for neutralization assays. |
View LGALS3 Products |
| Validator | Galectin-3 siRNA Set For knockdown verification and specificity controls. |
View LGALS3 Products |
| Related Target: Galectin-1 | LGALS1 Paralog selectivity testing (off-target liability screening). |
View LGALS1 Products |
| Related Target: Galectin-9 | LGALS9 Immune checkpoint cross-reactivity panel. |
View LGALS9 Products |
| Related Target: TGF-beta | TGFB1 Synergistic fibrosis pathway component. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (Galectin-1/9 off-target) | Human LGALS1, LGALS3, LGALS9 ortholog panel available with >95% purity, sequence verified by mass spectrometry. |
| Carbohydrate Recognition Domain (CRD) Binding Affinity | Biotinylated LGALS3 variants for SPR/BLI; High-avidity lactose-binding validated via rational design. |
| Soluble Protein Aggregation | HEK293 expressed, endotoxin <1EU/μg, formulated for high-concentration stability (up to 10 mg/mL). |
| Lack of Neutralization Controls | Clinical Benchmark Antibodies (biosimilar sequences) included for competitive binding assays. |
| Specificity Verification | Validated siRNA included for target engagement confirmation in cell-based assays. |
Live Galectin-3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Galectin-3 (LGALS3) therapeutics is intensifying, with major players shifting focus from broad-spectrum inflammation to precision fibrosis indications. First-generation small-molecule inhibitors targeting the carbohydrate recognition domain (CRD) have reached Phase II/III for Idiopathic Pulmonary Fibrosis (IPF) and NASH. Concurrently, monoclonal antibodies and carbohydrate-based antagonists are being explored for solid tumors and liver fibrosis. The next wave of R&D is expected to center on combination therapies with immune checkpoint inhibitors (e.g., PD-1/PD-L1) in oncology, as well as inhaled or subcutaneous formulations for chronic fibrotic diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Galecto (GB0139), Bristol Myers Squibb, Galectin Therapeutics | IPF, NASH, Solid Tumors | CRD Binding Assay (Need high-purity LGALS3 with intact carbohydrate-binding pocket) |
| Monoclonal Antibody | Various Biotech/Pharma Partners | Solid Tumors, Fibrosis | Neutralization Assay (Need cross-reactive Abs with CDR sequences) |
| Carbohydrate-Based Antagonist | Galectin Therapeutics (GR-MD-02) | NASH, Liver Fibrosis, Psoriasis | Competition Assay (Need biotinylated LGALS3 for displacement studies) |
| Combination Therapy (IO) | Novartis, Genfit | HCC, Melanoma | Cell Line Construction (Need LGALS3 Lentivirus for stable overexpression) |